Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
fetzima | New Drug Application | 2024-04-19 |
levomilnacipran | ANDA | 2024-07-01 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
major depressive disorder | EFO_0003761 | D003865 | F22 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | — | — | 1 | 1 |
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | — | — | — | 1 | 1 |
Drug common name | Levomilnacipran |
INN | levomilnacipran |
Description | Levomilnacipran (brand name Fetzima) is an antidepressant which was approved in the United States in 2013 for the treatment of major depressive disorder (MDD) in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor (SNRI).
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCN(CC)C(=O)[C@@]1(c2ccccc2)C[C@H]1CN |
PDB | — |
CAS-ID | 96847-54-0 |
RxCUI | — |
ChEMBL ID | CHEMBL99946 |
ChEBI ID | — |
PubChem CID | 6917779 |
DrugBank | DB08918 |
UNII ID | UGM0326TXX (ChemIDplus, GSRS) |